Overview

A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide

Status:
Completed

Trial end date:
2014-06-01

Target enrollment:

Participant gender:

Summary

The primary aim of this study is to determine if the addition of valproic acid to a combination of adriamycin, cyclophosphamide and vindesine could increase progression-free survival in patients relapsing after first-line chemotherapy including platinum derivatives, cisplatin or carboplatin, and etoposide.

Phase:

Phase 2

Details

Lead Sponsor:

European Lung Cancer Working Party

Treatments:

Cyclophosphamide
Doxorubicin
Etoposide
Liposomal doxorubicin
Valproic Acid
Vindesine